Committed to providing timely, high-quality information.
Control Bionics Investor Relations
Our most recent key ASX announcements together with our corporate governance policies can be found here.
Corporate Governance and Policies
Notification Regarding Unquoted Securities – 23 DEC 2021
Change of Directors Interests Notice – 23 DEC 2021
Morgan’s Investment Conference Presentation – 24 NOV 2021
Details of Company Address – 18 NOV 2021
Change of Directors Interests Notice – 10 NOV 2021
Change of Directors Interests Notice – 1 NOV 2021
Change of Directors Interests Notice – 29 OCT 2021
Quarterly Activities Report – 27 OCT 2021
Introduction of Rental Alternative to Australian Market – 20 OCT 2021
Results of AGM – 13 OCT 2021
2021 AGM Presentation – 13 OCT 2021
Change of Directors Interests Notice – 29 SEP 2021
Change of Directors Interests Notice – 27 SEP 2021
Change of Directors Interests Notice – 22 SEP 2021
Notice of Annual General Meeting – 13 SEP 2021
Appendix 4E – 26 AUG 2021
Appendix 4G – 26 AUG 2021
Corporate Governance Statement – 26 AUG 2021
2021 Annual Report – 26 AUG 2021
Cleansing notice – 11 AUG 2021
Application for quotation of securities – CBL – 11 AUG 2021
Release of shares from escrow – 8 AUG 2021
Reseller agreement with DNR Wheels – Singapore – 27 JUL 2021
Monthly Activities/Appendix 4C Cash Flow Report Q4 – 27 JUL 2021
Appendix 4C – Quarterly – 28 APR 2021
Appendix 2A – Release from mandatory escrow – 18 APR 2021
Reseller agreement with Numotion – US – 6 APR 2021
Release of shares from escrow – 5 APR 2021
Change of Director’s Interest Notice – Lismore – 21 MAR 2021
Becoming a substantial holder – 7 MAR 2021
Half Year Results Investor Presentation – 24 FEB 2021
Half year results commentary – 24 FEB 2021
Half Yearly Report and Accounts – 24 FEB 2021
Release of shares from voluntary escrow – 22 FEB 2021
Release of half year results and webinar – 22 FEB 2021
Section 708A(5)(e) Notice – 15 FEB 2021
Appendix 2A – 15 FEB 2021
Appointment of CFO – 7 FEB 2021
Appendix 4C – quarterly –20 JAN 2021
Notice Pursuant to s.708A(5)(e) Corporations Act – 13 JAN 2021
Appendix 2A – 13 JAN 2021
Details of Company Address – 11 JAN 2021
Release of shares from mandatory escrow – 3 JAN 2021
Becoming a substantial holder – Nightingale – 8 DEC 2020
Becoming a substantial holder – Ford – 8 DEC 2020
Initial Director’s Interest Notice – Lismore – 8 DEC 2020
Initial Director’s Interest Notice – Ford – 8 DEC 2020
Initial Director’s Interest Notice – Phillips – 8 DEC 2020
Initial Director’s Interest Notice – Wong – 8 DEB 2020
Initial Director’s Interest Notice – Hawke – 8 DEC 2020
Pre-quotation disclosure – 3 DEC 2020
Top 20 holders – 3 DEC 2020
Distribution schedule – 3 DEC 2020
Trading policy – 3 DEC 2020
Corporate governance statement – 3 DEC 2020
Option terms – 3 DEC 2020
Employee share option plan – 3 DEC 2020
30 June 2020 financial statements – 3 DEC 2020
30 June 2019 financial statements – 3 DEC 2020
Constitution – 3 DEC 2020
Prospectus – 3 DEC 2020
Appendix 1A and Information Form and Checklist – 3 DEC 2020
ASX market release – Admission and Quotation – 3 DEC 2020
- Giving Voice to Kids and Their Families: Meet IanMeet Ian. He’s learning language and communicating with his family using the NeuroNode Trilogy.
- Control Bionics Named one of Top Medtech Providers 2021This year, Control Bionics was honored to be included in the annual listing of 20 companies that are at the forefront of providing Medtech Year End Special Solutions and impacting the industry.
Board of Directors
Founder and Director of Innovation
For some people, Peter’s face may be familiar from his time as a CNN news anchor. But Peter’s real passion has always been bionics and robotics. In particular, he was inspired by the potential to help free one of the world’s great minds, Stephen Hawking.
In 1999, Peter identified that the patients’ damaged muscles still emitted small electrical signals that could be used to reliably control basic computer functions. And with that, Control Bionics was born.
Roger has over 30 years of experience in the telecommunications and technology space, having recently retired after 8 years as CEO & Managing Director of Crown Castle Australia/Axicom, and brings a high level of experience particularly in Technology, Operations, Sales and Management.
Roger holds BEng (SAIT), MES (Sydney) and MBA (Macquarie) degrees and is a Member of the Australian Institute of Company Directors.
Roger joined the Board of Control Bionics in October 2018.
Rob Wong is the Chief Executive Officer for Control Bionics. He holds a Bachelor of Business and an MBA from Melbourne University. Rob has over 25 years of experience with multinational businesses in senior management, marketing, and operational roles. He is also an entrepreneur and angel investor having been involved with several successful tech start-up businesses. He formerly held the position of CEO at AIMIA Digital Industry Association of Australia.
Rob joined Control Bionics in early 2017 and he has led the way in developing their latest product, the NeuroNode Trilogy. Rob has spent much of his time with Control Bionics presenting to industry leaders, forming research and development relations, and working hands-on with clients across the world.
As a highly-experienced private equity fund Managing Director and Chairman, Lindsay is a key member of the Control Bionics’ leadership team. Lindsay first invested in Control Bionics in 2005.
Lindsay was Managing Director of Lazard Australia Private Equity from 2007 to 2012. Since 2012 Lindsay has been Chairman of Phoenix Development Fund and Nightingale Partners. He holds a Bachelor of Commerce from the University of Western Australia and is a member of the Institute of Chartered Accountants of Australia.
Damian has held a number of Directorships and has extensive commercial, international and listed company experience (both ASX and NASDAQ), covering many industries including healthcare and technology. In his executive career, he held CEO, CFO and Company Secretarial roles and continues to act as an advisor to CEOs, boards and business owners. Damian joined the Control Bionics board in September 2020 and is a Graduate Member of Australian Institute of Company Directors, Member of Chartered Accountants Australia and New Zealand, Fellow of Chartered Accountants in Ireland and holds a BA (Honours) Accountancy. Damian is currently CFO of Scout Bio Inc, a Frazier Healthcare Partners backed company, and a Non-Executive Director of ASX listed LBT Innovations Limited (ASX:LBT).
Brett is a practicing solicitor and a former Partner of Ernst & Young in Hong Kong and Australia, and of KPMG in Hong Kong. He is a former Senior Legal Member of the NSW Guardianship Tribunal and the NSW Civil and Administrative Tribunal.
Brett has extensive ASX-listed company experience. He is currently chairman of Jatcorp Limited (ASX:JAT) and company secretary of three other ASX-listed companies.